Poliomyelitis- Market Insights, Epidemiology and Market Forecast 2028
SKU ID :MI-13554941 | Published Date: 06-Jun-2019 | No. of pages: 92Description
TOC
Table of Contents
1 Key Insights
2 Poliomyelitis Market Overview at a Glance
2.1 Market Share (%) Distribution of Poliomyelitis in 2018
2.2 Market Share (%) Distribution of Poliomyelitis in 2028
3 Poliomyelitis: Disease Background and Overview
3.1 Introduction
3.2 Symptoms
3.3 Etiology
3.4 Risk Factor
3.5 Pathophysiology
3.6 Diagnosis
3.7 Treatment
4 Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Poliomyelitis in 7MM
4.3. Total Prevalent Patient Population of Poliomyelitis in 7MM – By Countries
5 Epidemiology of Poliomyelitis by Countries (2016-2028)
5.1 United States- Epidemiology (2016-2028)
5.1.1 Assumptions and Rationale
5.1.2 Prevalent/Incident Cases of Poliomyelitis in the United States
5.1.3 Sub-Type Specific cases of Poliomyelitis in the United States
5.1.4 Sex- Specific Cases of Poliomyelitis in the United States
5.1.5 Diagnosed Cases of Poliomyelitis in the United States
5.1.6 Treatable Cases of Poliomyelitis in the United States
5.2 EU5 Countries
5.2.1 Germany
5.2.1.1 Assumptions and Rationale
5.2.1.2 Prevalent/Incident Cases of the of Poliomyelitis in the Germany
5.2.1.3 Sub-Type Specific cases of Poliomyelitis in the Germany
5.2.1.4 Sex- Specific Cases of the Poliomyelitis in the Germany
5.2.1.5 Diagnosed Cases of the Poliomyelitis in the Germany
5.2.1.6 Treatable Cases of the Poliomyelitis
5.2.2 France
5.2.2.1 Assumptions and Rationale
5.2.2.2 Prevalent/Incident Cases of the of Poliomyelitis in the France
5.2.2.3 Sub-Type Specific cases of Poliomyelitis in the France
5.2.2.4 Sex- Specific Cases of the Poliomyelitis in the France
5.2.2.5 Diagnosed Cases of the Poliomyelitis in the France
5.2.2.6 Treatable Cases of the Poliomyelitis
5.2.3 Italy
5.2.3.1 Assumptions and Rationale
5.2.3.2 Prevalent/Incident Cases of the of Poliomyelitis in the Italy
5.2.3.3 Sub-Type Specific cases of Poliomyelitis in the Italy
5.2.3.4 Sex- Specific Cases of the Poliomyelitis in the Italy
5.2.3.5 Diagnosed Cases of the Poliomyelitis in the Italy
5.2.3.6 Treatable Cases of the Poliomyelitis
5.2.4 Spain
5.2.4.1 Assumptions and Rationale
5.2.4.2 Prevalent/Incident Cases of the of Poliomyelitis in the Spain
5.2.4.3 Sub-Type Specific cases of Poliomyelitis in the Spain
5.2.4.4 Sex- Specific Cases of the Poliomyelitis in the Spain
5.2.4.5 Diagnosed Cases of the Poliomyelitis in the Spain
5.2.4.6 Treatable Cases of the Poliomyelitis
5.2.5 United Kingdom
5.2.5.1 Assumptions and Rationale
5.2.5.2 Prevalent/Incident Cases of the of Poliomyelitis in the United Kingdom
5.2.5.3 Sub-Type Specific cases of Poliomyelitis in the United Kingdom
5.2.5.4 Sex- Specific Cases of the Poliomyelitis in the United Kingdom
5.2.5.5 Diagnosed Cases of the Poliomyelitis in the United Kingdom
5.2.5.6 Treatable Cases of the Poliomyelitis
5.3 Japan
5.3.1 Assumptions and Rationale
5.3.2 Prevalent/Incident Cases of the of Poliomyelitis in the Japan
5.3.3 Sub-Type Specific cases of Poliomyelitis in the Japan
5.3.4 Sex- Specific Cases of the Poliomyelitis in the Japan
5.3.5 Diagnosed Cases of the Poliomyelitis in the Japan
5.3.6 Treatable Cases of the Poliomyelitis
6 Current Treatment & Medical practices
6.1 Treatment Algorithm
6.2 Treatment Guidelines
7 Unmet Needs
8 Marketed Product
8.1 Drug A: Company 1
8.1.1 Drug Description
8.1.2 Mechanism of Action
8.1.3 Clinical Trials Details
8.1.4 Advantages & Disadvantages
8.1.5 Safety and Efficacy
8.1.6 Product Profile
8.2 Drug B: Company 2
8.2.1 Drug Description
8.2.2 Mechanism of Action
8.2.3 Clinical Trials Details
8.2.4 Advantages & Disadvantages
8.2.5 Safety and Efficacy
8.2.6 Product Profile
8.3 Drug C: Company 3
8.3.1 Drug Description
8.3.2 Mechanism of Action
8.3.3 Clinical Trials Details
8.3.4 Advantages & Disadvantages
8.3.5 Safety and Efficacy
8.3.6 Product Profile
8.4 Drug D: Company 4
8.4.1 Drug Description
8.4.2 Mechanism of Action
8.4.3 Clinical Trials Details
8.4.4 Advantages & Disadvantages
8.4.5 Safety and Efficacy
8.4.6 Product Profile
8.5 Drug E: Company 5
8.5.1 Drug Description
8.5.2 Mechanism of Action
8.5.3 Clinical Trials Details
8.5.4 Advantages & Disadvantages
8.5.5 Safety and Efficacy
8.5.6 Product Profile
8.6 : Company 6
8.6.1 Drug Description
8.6.2 Mechanism of Action
8.6.3 Clinical Trials Details
8.6.4 Advantages & Disadvantages
8.6.5 Safety and Efficacy
8.6.6 Product Profile
8.7 : Company 7
8.7.1 Drug Description
8.7.2 Mechanism of Action
8.7.3 Clinical Trials Details
8.7.4 Advantages & Disadvantages
8.7.5 Safety and Efficacy
8.7.6 Product Profile
8.8 : Company 8
8.8.1 Drug Description
8.8.2 Mechanism of Action
8.8.3 Clinical Trials Details
8.8.4 Advantages & Disadvantages
8.8.5 Safety and Efficacy
8.8.6 Product Profile
9 Emerging Drugs
9.1 Key Cross Competition
9.2 Emerging company
9.2.1 Emerging Drug A: Company 20
9.2.1.1 Other Development Activities
9.2.1.2 Clinical Development
9.2.1.3 Clinical Trials Information
9.2.1.4 Safety and Efficacy
9.2.1.5 Advantages and Disadvantages
9.2.1.6 Product Profile
9.2.2 Emerging Drug B: Company 21
9.2.2.1 Other Development Activities
9.2.2.2 Clinical Development
9.2.2.3 Clinical Trials Information
9.2.2.4 Safety and Efficacy
9.2.2.5 Advantages and Disadvantages
9.2.2.6 Product Profile
9.2.3 Emerging Drug C: Company 22
9.2.3.1 Other Development Activities
9.2.3.2 Clinical Development
9.2.3.3 Clinical Trials Information
9.2.3.4 Safety and Efficacy
9.2.3.5 Advantages and Disadvantages
9.2.3.6 Product Profile
9.2.4 Emerging Drug D: Company 23
9.2.4.1 Other Development Activities
9.2.4.2 Clinical Development
9.2.4.3 Clinical Trials Information
9.2.4.4 Safety and Efficacy
9.2.4.5 Advantages and Disadvantages
9.2.4.6 Product Profile
9.2.5 Emerging Drug E: Company 24
9.2.5.1 Other Development Activities
9.2.5.2 Clinical Development
9.2.5.3 Clinical Trials Information
9.2.5.4 Safety and Efficacy
9.2.5.5 Advantages and Disadvantages
9.2.5.6 Product Profile
10 7MM Market Analysis
10.1 7MM Market Size of Poliomyelitis
10.2 7MM Percentage Share of Drugs Marketed for Poliomyelitis
10.3 7MM Market Sales of Poliomyelitis by Products
11 The United States Market Outlook
11.1 Market Size of Poliomyelitis in United States
11.2 Percentage Share of Drugs Marketed for Poliomyelitis in United States
11.3 Market Sales of Poliomyelitis by Products in United States
11.4 Analysis of Upcoming Therapies and Impact on the Market
12 EU5 Countries Market Outlook
12.1 Market Size of Poliomyelitis in EU5
12.2 Market Size of Poliomyelitis in Germany
12.2.1 Market Size of Poliomyelitis in Germany
12.2.2 Percentage Share of Drugs Marketed for Poliomyelitis in Germany
12.2.3 Market Sales of Poliomyelitis by Products in Germany
12.2.4 Analysis of Upcoming Therapies and Impact on the Market
12.3 Market Size of Poliomyelitis in France
12.3.1 Market Size of Poliomyelitis in France
12.3.2 Percentage Share of Drugs Marketed for Poliomyelitis in France
12.3.3 Market Sales of Poliomyelitis by Products in France
12.3.4 Analysis of Upcoming Therapies and Impact on the Market
12.4 Market Size of Poliomyelitis in Italy
12.4.1 Market Size of Poliomyelitis in Italy
12.4.2 Percentage Share of Drugs Marketed for Poliomyelitis in Italy
12.4.3 Market Sales of Poliomyelitis by Products in Italy
12.4.4 Analysis of Upcoming Therapies and Impact on the Market
12.5 Market Size of Poliomyelitis in Spain
12.5.1 Market Size of Poliomyelitis in Spain
12.5.2 Percentage Share of Drugs Marketed for Poliomyelitis in Spain
12.5.3 Market Sales of Poliomyelitis by Products in Spain
12.5.4 Analysis of Upcoming Therapies and Impact on the Market
12.6 Market Size of Poliomyelitis in United Kingdom
12.6.1 Market Size of Poliomyelitis in United Kingdom
12.6.2 Percentage Share of Drugs Marketed for Poliomyelitis in United Kingdom
12.6.3 Market Sales of Poliomyelitis by Products in United Kingdom
12.6.4 Analysis of Upcoming Therapies and Impact on the Market
13 The Japan Market Outlook
13.1 Market Size of Poliomyelitis in Japan
13.2 Percentage Share of Drugs Marketed for Poliomyelitis in Japan
13.3 Market Sales of Poliomyelitis by Products in Japan
13.4 Analysis of Upcoming Therapies and Impact on the Market
14 Cost Analysis of Poliomyelitis
15 Generic Competition in Poliomyelitis Market
16 Market Drivers
17 Market Barriers
18 Report Methodology
18.1 Methodology/Research Approach
18.2 Data Source
18.2.1 Secondary Sources
18.2.2 Primary Sources
Tables & Figures
List of Tables
Table Total Prevalent/Incident Cases of the Poliomyelitis in 7MM (2016-2028)
Table Total Prevalent/Incident Cases of the Poliomyelitis in 7MM by Countries (2016-2028)
Table Prevalent/Incident Cases of the Poliomyelitis in United States (2016-2028)
Table Sub-Type Specific cases of Poliomyelitis in the United States (2016-2028)
Table Sex- Specific Cases of Poliomyelitis in the United States (2016-2028)
Table Diagnosed Cases of the Poliomyelitis in United States (2016-2028)
Table Treatable Cases of the Poliomyelitis in United States (2016-2028)
Table Prevalent/Incident Cases of the Poliomyelitis in Germany (2016-2028)
Table Sub-Type Specific cases of Poliomyelitis in the Germany (2016-2028)
Table Sex- Specific Cases of Poliomyelitis in the Germany (2016-2028)
Table Diagnosed Cases of the Poliomyelitis in Germany (2016-2028)
Table Treatable Cases of the Poliomyelitis in Germany (2016-2028)
Table Prevalent/Incident Cases of the Poliomyelitis in France (2016-2028)
Table Sub-Type Specific cases of Poliomyelitis in the France (2016-2028)
Table Sex- Specific Cases of Poliomyelitis in the France (2016-2028)
Table Diagnosed Cases of the Poliomyelitis in France (2016-2028)
Table Treatable Cases of the Poliomyelitis in France (2016-2028)
Table Prevalent/Incident Cases of the Poliomyelitis in Italy (2016-2028)
Table Sub-Type Specific cases of Poliomyelitis in the Italy (2016-2028)
Table Sex- Specific Cases of Poliomyelitis in the Italy (2016-2028)
Table Diagnosed Cases of the Poliomyelitis in Italy (2016-2028)
Table Treatable Cases of the Poliomyelitis in Italy (2016-2028)
Table Prevalent/Incident Cases of the Poliomyelitis in Spain (2016-2028)
Table Sub-Type Specific cases of Poliomyelitis in the Spain (2016-2028)
Table Sex- Specific Cases of Poliomyelitis in the Spain (2016-2028)
Table Diagnosed Cases of the Poliomyelitis in Spain (2016-2028)
Table Treatable Cases of the Poliomyelitis in Spain (2016-2028)
Table Prevalent/Incident Cases of the Poliomyelitis in United Kingdom (2016-2028)
Table Sub-Type Specific cases of Poliomyelitis in the United Kingdom (2016-2028)
Table Sex- Specific Cases of Poliomyelitis in the United Kingdom (2016-2028)
Table Diagnosed Cases of the Poliomyelitis in United Kingdom (2016-2028)
Table Treatable Cases of the Poliomyelitis in United Kingdom (2016-2028)
Table Prevalent/Incident Cases of the Poliomyelitis in Japan (2016-2028)
Table Sub-Type Specific cases of Poliomyelitis in the Japan (2016-2028)
Table Sex- Specific Cases of Poliomyelitis in the Japan (2016-2028)
Table Diagnosed Cases of the Poliomyelitis in Japan (2016-2028)
Table Treatable Cases of the Poliomyelitis in Japan (2016-2028)
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Drug Description
Table Mechanism of Action
Table Clinical Trials Details
Table Advantages & Disadvantages
Table Safety and Efficacy
Table Product Profile
Table Comparison of emerging drugs (Immunomodulators) under development
Table Comparison of emerging drugs (other classes) under development
Table Safety and Efficacy
Table Product Advantages and Advantages
Table Clinical Trial Description, 2018
Table Safety and Efficacy
Table Product Advantages and Advantages
Table Clinical Trial Description, 2018
Table Safety and Efficacy
Table Product Advantages and Advantages
Table Clinical Trial Description, 2018
Table Safety and Efficacy
Table Product Advantages and Advantages
Table Clinical Trial Description, 2018
Table Safety and Efficacy
Table Product Advantages and Advantages
Table Clinical Trial Description, 2018
Table7MM- Market Size of Poliomyelitis in USD MM (2016-2028)
Table 7MM- Market Share Poliomyelitis by Therapies in USD MM (2016-2028)
Table 7MM- Market Sales of Poliomyelitis by Therapies in USD MM (2016-2028)
Table US Market Size of Poliomyelitis in USD, Million (2016-2028)
Table United States-Market Share Poliomyelitis by Therapies in USD MM (2016-2028)
Table United States-Market Sales of Poliomyelitis by Therapies in USD MM (2016-2028)
Table EU5 Market Size of Poliomyelitis (MS) in USD, Million (2016-2028)
Table Germany Market Size of Poliomyelitis in USD, Million (2016-2028)
Table Germany -Market Share Poliomyelitis by Therapies in USD MM (2016-2028)
Table Germany -Market Sales of Poliomyelitis by Therapies in USD MM (2016-2028)
Table France Market Size of Poliomyelitis in USD, Million (2016-2028)
Table France -Market Share Poliomyelitis by Therapies in USD MM (2016-2028)
Table France -Market Sales of Poliomyelitis by Therapies in USD MM (2016-2028)
Table Italy Market Size of Poliomyelitis in USD, Million (2016-2028)
Table Italy -Market Share Poliomyelitis by Therapies in USD MM (2016-2028)
Table Italy -Market Sales of Poliomyelitis by Therapies in USD MM (2016-2028)
Table Spain Market Size of Poliomyelitis in USD, Million (2016-2028)
Table Spain -Market Share Poliomyelitis by Therapies in USD MM (2016-2028)
Table Spain -Market Sales of Poliomyelitis by Therapies in USD MM (2016-2028)
Table United Kingdom Market Size of Poliomyelitis in USD, Million (2016-2028)
Table United Kingdom -Market Share Poliomyelitis by Therapies in USD MM (2016-2028)
Table United Kingdom -Market Sales of Poliomyelitis by Therapies in USD MM (2016-2028)
Table Japan Market Size of Poliomyelitis in USD, Million (2016-2028)
Table Japan -Market Share Poliomyelitis by Therapies in USD MM (2016-2028)
Table Japan -Market Sales of Poliomyelitis by Therapies in USD MM (2016-2028)
Table Market Drivers of Poliomyelitis
Table Market Barriers of Poliomyelitis
???
Companies
- PRICE
-
$5980$12980